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ABSTRACT 
Objective: This paper describes the development and validation of two UV-Visible spectrophotometric analysis methods, using absolute ethanol 
(method A) and HCl 0.1 M (method B) as solvents, to quantify fluoxetine (FLX) in its generic and brand name form. The objective is to validate both 
methods and compare the concentrations of the samples obtained from each one.  
Methods: Validation of each method with the determination of linearity, limit of detection and quantification, intermediary precision, robustness, 
accuracy and uniformity of mass for both samples was performed. 
Results: Uniform distribution of FLX in capsules were verified and good linear relationships were found between the readings and the 
concentrations of FLX, in the ranges of 100 µg/ml to 300 µg/ml and 5 µg/ml to 25 µg/ml, for method A and B, respectively. The limit of 
quantification obtained was 9.96 µg/ml for method A and 0.87 µg/ml for method B. The limit of detection obtained was 2.988 µg/ml for method A 
and 0.26 µg/ml for method B. Was also verified robustness, good inter-day precision and accuracy of both methods.  
Conclusion: The methods were successfully validated to the determination of FLX in its pharmaceutical formulations. 
Keywords: Fluoxetine, UV-Visible spectrophotometry, Quantification, Validation 
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INTRODUCTION 
Depression is a significant and prevalent, chronic or recurrent 
illness that affects both economic and social functions of patients 
and can eventually lead to suicidal behaviors [1, 2].  
FLX, (N-Methyl-3-(p-trifluoro-methylphenyl)-3-phenyl-propylamine), 
is a cyclic secondary amine and is a selective serotonin reuptake 
inhibitor (SSRI) anti-depressant drug. Is orally used in its 
hydrochloride form and has the empirical formula of C17H18F3NO·HCl 
[3-6]. Fluoxetine Hydrochloride (FLX-HCl) was first patented and 
commercialized by Eli Lilly under the commercial name of Prozac®
It is among the most prescribed drugs worldwide for treating major 
depression and related disorders, such as anxiety (panic disorder, 
social phobia, obsessive-compulsive disorder, post-traumatic stress 
disorder), eating disorders (anorexia, bulimia) and personality 
disorders (borderline personality disorder, attention-deficit 
hyperactivity disorder). This drug is popular due to the low potential 
of abuse and the relative absence of adverse reactions [10, 11].  
 
in the USA since 1988 and became the most widely prescribed 
antidepressant drug [7-9].  
During depression treatment, a quantity of 20–80 mg of FLX per day 
is commonly used, and its therapeutic level covers the range from 50 
to 500 ng/ml [12, 13]. It is well absorbed after oral administration, 
and it takes 6–8 h to reach the plasma peak. It has a long half-life 
time that allowed for the introduction of once-weekly dosing as an 
enteric-coated formulation [3, 14, 15].  
Demand for FLX analytical assay is growing with the increased use 
of the drug in order to monitor both compliance and unexpected toxic 
concentrations after chronic use of the drug [6, 16, 17]. Thus, reliable, 
accurate and sensitive analytical procedures are needed to determine 
drug levels either in quality control or in therapeutic drug monitoring 
[1, 6, 17]. The major problem, as for other antidepressants, is their 
great inter-individual variability in clinical response, which makes it 
difficult to evaluate the correct posology [17-20].  
FLX has been determined in its pharmaceutical formulations by 
titrimetry, nuclear magnetic resonance spectrometry, potentiometry, 
thin-layer chromatography, liquid chromatography, gas 
chromatography, conductometry, fluorimetry, chemiluminescence, 
voltammetry and capillary electrophoresis. These methods were 
time-consuming, tedious, and/or dedicated to sophisticated and 
expensive analytical instruments [5, 6, 14, 19, 21, 22]. In general, 
spectrophotometry is considered the most convenient analytical 
technique because of its inherent simplicity, low cost, wide sensitivity, 
and availability in most quality control laboratories [14, 23].  
Method validation is the process of proving that an analytical 
method is acceptable for its intended purpose. In the pharmaceutical 
industry, validation of analytical method is required in support of 
product registration applications. For pharmaceutical methods, 
guidelines from the United States Pharmacopeia (USP), International 
Conference on Harmonization (ICH) and the Food and Drug 
Administration (FDA) provide a framework to perform such 
validation methods. Validating a method consists of the evaluation of 
various parameters such as accuracy, precision, linearity, sensitivity, 
limits of detection and quantification, recovery from the matrix and 
specificity [20].  
In 2001 the exclusivity patent of FLX expired and its generic became 
available [24, 25]. However despite a large amount of success due to 
lower prices, a randomized, double-blind, crossover study 
comparing a branded antidepressant with its generic counterpart 
involving FLX was made and shocking results were found. In general, 
it was observed in some patients who started taking the generic FLX 
an initial lower antidepressant effect, increased rates of side effects, 
relapses of depression and allergic reactions. In all cases, patients 
improved after returning to the brand name drug [26-28].  
The FDA and European Medicines Agency (EMA) allow generic 
medications to have a bioequivalence ranging between 80 and 125% 
of the brand name medication. This means that the generic form of 
FLX labeled to contain 20 mg could have a decrease to as little as 16 
mg or increase to as much as 25 mg [28, 29].  
In our research, it was not found any paper comparing the amount of 
FLX between brand name and generic forms. So this paper describes 
the development and validation of two spectrophotometric methods, 
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using absolute ethanol (method A, based on the paper of Fregonezy-
Nery [30]) and HCl 0.1 M (method B, based on Brazilian 
Pharmacopoeia 4th
MATERIALS AND METHODS 
 edition [31]) as solvents, to quantify FLX in its 
capsules form. 
Apparatus 
Double beam UV-1603 (Shimadzu, Tokyo, Japan) ultraviolet-visible 
spectrophotometer with matched 1-cm quartz cells was used for all 
the absorbance measurements at room temperature. Analytical 
Balance XR 125SM-FR (Precisa, Moosmattstrasse, Swiss) and 
ultrasonic bath (Selecta, Barcelona, Spain) were also used in this 
experiment. Microsoft Excel 2013 and UVProbe 2.10 were the 
software used to treat data through all the work. 
Chemicals and reagents 
All reagents used were of analytical grade. Pure Fluoxetine 
Hydrochloride (Lot: 130927-G3) was obtained from Acofarma Lda. 
(Águeda, Portugal). Solvents used were absolute ethanol (Merck-Lot: 
K43665283229 and Fisher–Lot: 1226488) and HCl 0.1 M that was 
prepared by diluting HCl 37% (Panreac-Lot: 000042795) in purified 
water (used thorough all the experiment and obtained by reverse 
osmosis with the system provided from Vidrolab 2, S. A.). 
Pharmaceutical dosage forms 
Two samples of commercial capsules of FLX-HCl were obtained from 
a local pharmacy: generic form Fluoxetine Basi® Lot: 3001 (sample 
1) and brand name from Prozac®
Uniformity of mass 
 Lot: 44968 (sample 2), both 
labeled to contain 20 mg of FLX per capsule. 
Content determination and uniformity of mass assume a suitable 
moisture process and distribution of the active principle in the capsules 
during production, showing good manufacturing practices [32]
In this experiment, twenty capsules of each sample were 
individually weighed with content. After removing, as completely as 
possible, the content from each capsule, the empty capsule was 
weighted, and the content was mixed for use in preparation of the 
sample solution.  
.  
Preparation of fluoxetine stock solution  
In order to discover the amount of FLX-HCl to weight it was used the 
equivalence factor, which indicates that 20 mg of FLX are equivalent 
to 22.4 mg of FLX-HCl [33, 34].  
Method A: 140 mg of FLX-HCl was transferred to a 250 ml 
calibrated flask and dissolved with absolute ethanol to obtain a FLX 
stock solution of 500 µg/ml. 
Method B: 28 mg of FLX-HCl was transferred to a 100 ml calibrated 
flask and dissolved with HCl 0.1 M to obtain a FLX stock solution of 
250 µg/ml. 
Preparation of sample solution of the pharmaceutical dosage 
forms  
Method A: The amount of the average weight (obtained in 
uniformity of mass) of each sample, was accurately weighed 
(equivalent to 20 mg of FLX), transferred into two 50 ml volumetric 
flasks (one for each sample), dissolved in ethanol and sonicated for 
15 min. Then, the volumetric flasks were completed with ethanol, 
and the content was homogenized and filtered. In the end, 15 ml of 
each filtrate were transferred to two 25 ml volumetric flasks that 
were completed with ethanol, obtaining a concentration of 240 
µg/ml of FLX. 
Method B: In order to obtain a concentration of 150 µg/ml, was 
weighed an amount of each sample (obtained in uniformity of mass) 
that corresponded to 15 mg of FLX to 100 ml volumetric flasks. 
Then, the powder was dissolved with 70 ml of HCl 0.1 M and 
sonicated for 5 min. After removed from the ultrasonic bath, the 
flasks were mechanically shaken for 15 min and completed with HCl 
0.1 M. Once homogenized and filtered, 10 ml of each filtrate were 
transferred to two 100 ml volumetric flasks that were filled with the 
solvent, obtaining a concentration of 15 µg/ml of FLX. 
Method validation 
The method was validated according to the guidelines of the ICH for 
analytical validation procedures and Resolution RE899 of the 
National Health Surveillance Agency (ANVISA) [35, 36]. 
Linearity 
Method A: From the FLX stock solution, five aliquots were diluted to 
25 ml using ethanol to get standard solutions with concentrations of 
300 μg/ml, 250 μg/ml, 200 μg/ml, 150 μg/ml and 100 µg/ml. It was 
made three standard solutions of each concentration and their 
absorbances were measured in triplicate at 276 nm using UV 
spectrophotometer against blank (absolute ethanol). 
Method B: From the stock solution, five aliquots were diluted to 50 
ml using HCl 0.1 M to get standard solutions with concentrations of 
25 μg/ml, 20 μg/ml, 15 μg/ml, 10 μg/ml and 5 µg/ml. It was made 
three standard solutions of each concentration, and their 
absorbance were measured in triplicate at 227 nm using UV 
Spectrophotometer against blank (HCl 0.1 M).  
For each method, a calibration curve was obtained by plotting 
absorbance values against FLX standard solution concentrations.  
Limit of quantification (LOQ) and limit of detection (LOD) 
LOD and LOQ were calculated based on standard deviation (SD) of 
response and the slope of the calibration curve. The formulas to 
calculate each one of these limits are mentioned above:  
LOD = 3σ/s, LOQ = 10σ/s 
Where σ is the SD of intercept and s is the slope of calibration curve [37].  
Intermediary precision 
The precision of the analytical method is expressed as SD or relative 
standard deviation (RSD) of a series of, in these experiments, five 
measurements. The same analyst using the same methods, samples, 
material and reagents, made in two different days the quantification 
of FLX in the prepared sample solutions. 
Robustness 
To verify the robustness of the method A, it was used another absolute 
ethanol manufacturer to prepare samples solutions. Absorbance 
measurements were made five times and the FLX concentrations, 
expressed in μg/ml, were obtained from the calibration curve.  
Accuracy 
Accuracy was evaluated by the addition and recovery of known 
quantities of FLX standard in commercial samples.  
Method A: solutions were prepared in triplicate in 25 ml volumetric 
flasks containing a mixture of 100 μg/ml sample solution and 
aliquots from 150 μg/ml standard solution, obtaining 
concentrations of 102 μg/ml, 104 μg/ml and 106 μg/ml. 
Method B: solutions were prepared in triplicate in 25 ml volumetric 
flasks containing a mixture of 15 μg/ml sample solution and aliquots 
from 10 μg/ml standard solution, obtaining concentrations of 14.8 
μg/ml, 14.6 μg/ml and 14.4 μg/ml. 
RESULTS AND DISCUSSION 
Uniformity of mass 
According to Portuguese Pharmacopeia 8th Edition, no more than 2 of 20 
units may differ from the mean mass in superior percentage of 10% and 
in none of the cases the difference may exceed double that [38]. These 
requirements were all in conformity with the results for both samples as 
shown in Graph 1 and 2 (which show the mass of the twenty capsules 
used of each sample). The percentage difference obtained between the 
mean mass and maximum quantity of the powder weighed was 4.5% 
and 3.35%; minimum quantity of the powder weighed was 2.90% and 
2.25% in sample 1 and 2, respectively.  
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Graph 1: Content mass of twenty capsules of sample 1 and limits 
(10% above and below of the mean mass) according to 
Portuguese pharmacopeia 8th edition 
 
 
Results indicate a uniform distribution of FLX in capsules, which will 
ensure effective doses every administration and, therefore, 
maintenance of therapy concentration. 
Graph 2: Content mass of twenty capsules of sample 2 and limits 




After registering the measurements, the average mass of the powder 
in one capsule, SD and RSD were calculated, as showed in table 1.  
 
Table 1: Mean mass of the powder, SD and RSD for both samples 
Sample Mean (mg) SD RSD 
1 0.2216 0.0053 2.3744 




Fig. 1: Spectra of standard solution of FLX with concentration of 
200 μg/ml using method A at a range of 260-300 nm 
 
Fig. 1 shows spectra of a standard solution of FLX with a 
concentration of 200 μg/ml in ethanol at a range of 260-300 nm. Fig. 
2 shows spectra of standard solution of FLX with a concentration of 
15 μg/ml in HCl 0.1M at a range of 200-300 nm. 
 
Fig. 2: Spectra of standard solution of FLX with concentration of 
15 μg/ml using method B at a range of 200-300 nm 
 
The analysis of the spectrum indicates that a peak at 276 nm and 
227 nm in fig. 1 and 2, respectively, was obtained, as expected 
[30, 31]. 
  
Table 2: Mean, SD and RSD of absorbance measurements using method A 
Concentration (µg/ml) Mean SD RSD 
300 0.705 0.002 0.250 
250 0.583 0.005 0.860 
200 0.454 0.005 1.036 
150 0.336 0.002 0.490 
100 0.209 0.001 0.646 
n=9 
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Table 3: Mean, SD and RSD of absorbance measurements using Method B 
Concentration (µg/ml) Mean SD RSD 
25 0.890 0.006 0.687 
20 0.717 0.006 0.793 
15 0.547 0.004 0.672 
10 0.376 0.007 1.871 





After absorbance measurement of standard solutions using method 
A and B, data was processed statistically, to calculate parameters 
like mean, SD and RSD presented in table 2 and 3.  
Calibration curves for both methods were obtained from a linear 
regression method. Standard calibration curve of methods A and B 
presented linearity between concentration range 100 µg/ml to 300 
µg/ml with a determination coefficient (r2
 
Graph 3: Calibration curve of FLX at 276 nm obtained with 
method A, results of linear regression analysis (regression 
equation and determination coefficient) and standard deviation 
of the measurements 
 
Limit of quantification (LOQ) and limit of detection (LOD) 
The LOQ obtained was 9.96 µg/ml for method A and 0.87 µg/ml for 
method B. The LOD obtained was 2.988 µg/ml for method A and 
0.26 µg/ml for method B. Once the standard solutions have different 
concentration range for each method, it was not possible to compare 
the LOD and LOQ for each method. 
) of 0.9999 and 5 µg/ml to 
25 µg/ml with a determination coefficient of 0.9999, respectively, as 
shown in Graph 3 and 4. The correlation coefficient obtained for 




Graph 4: Calibration curve of FLX at 227 nm obtained with 
method B, results of linear regression analysis (regression 




Robustness was examined by evaluating the influence of small 
variation in the method variables on its analytical performance. In 
these experiments, one parameter was changed whereas the others 
were kept unchanged. Analyzing and comparing results presented in 
table 4 it can be seen that the change in ethanol supplier did not 
induce considerable changes in concentration values of both samples. 
Intermediary precision 
Intermediary precision was evaluated by the inter-day (between 
days) study. The results of estimation by proposed methods are 
shown in table 5. 
From obtained results, the concentration of both samples was 
calculated using as reference the calibration curve obtained from the 
stock standard solutions that were made in the previous analysis. 
We made five measurements of each solution at 240 µg/ml and 15 
µg/ml (method A and B) and calculated SD and RSD.  
Using Related-Samples Wilcoxon Signed Rank Test we verified that 
there are no statistically significant differences between the 
concentrations of two days (p=0.465), so both methods showed 
good inter-day precision. 
 
Table 4: Mean of absorbance and concentration values of samples 1 and 2 using two different ethanol manufacturers for method A 
Manufacturer Sample Mean Concentration (µg/ml) SD RSD 
Merck 1 0.587 250.56 0.003 0.533 
2 0.603 256.64 0.004 0.628 
Fisher 1 0.570 243.76 0.001 0.096 




Accuracy results for method A are in the range of 102.75% to 
103.46% for sample 1 and 106.27% to 107.55% for sample 2. For 
method B, accuracy is in the range of 102.76% and 103.36% for 
sample 1 and 104.80% and 108.75% for sample 2. The theoretical 
concentration of standard FLX-HCl added was obtained from each 
calibration curve resultant from linearity method. Results are shown 
in table 6. 
In United States Pharmacopeia [39] and Brazilian Pharmacopeia 
[31] recovery percentages for FLX capsules must be between 90-
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110%. Once, the obtained results, between 103% and 109%, are in 
the recommended range, it can be verified that both of the presented 
methods are valid.  
Good percent recovery with a small SD indicates the high accuracy of 
the developed methods for the quantification of FLX in 
pharmaceutical preparations. 
 
Table 5: Concentration values of sample 1 and 2 obtained using method A and B in two different days 
Day Method Sample Concentration (µg/ml) SD RSD 
1 A 1 249.92 0.006 1.102 
2 259.52 0.002 0.315 
B 1 15.39 0.004 0.791 
2 17.10 0.007 1.183 
2 A 1 250.56 0.003 0.533 
2 256.64 0.004 0.628 
B 1 15.58 0.004 0.666 
2 16.30 0.002 0.378 
n=5; p=0.465 
 
Table 6: Mean of absorbance and recoveries test of FLX in sample 1 and 2 using standard addition method 
Method Theoretical concentration 
(µg/ml) 
Mean of absorbances (±SD) Obtained Concentration (µg/ml) % recovered 
Sample 1 Sample 2 Sample 1 Sample 2 Sample 1 Sample 2 
A 102.00 0.223 (0.0040) 0.232 (0.0021) 104.80 108.40 102.75 106.27 
104.00 0.230 (0.0020) 0.240 (0.0012) 107.60 111.60 103.46 107.31 
106.00 0.234 (0.0038) 0.246 (0.0047) 109.20 114.00 103.02 107.55 
B 14.80 0.558 (0.0059) 0.585 (0.0021) 15.30 16.09 103.36 108.75 
14.60 0.548 (0.0049) 0.565 (0.0068) 15.00 15.50 102.76 106.19 
14.40 0.542 (0.0031) 0.551 (0.0050) 14.83 15.09 102.96 104.80 
n=3 
 
Application of the methods in sample solutions of the 
pharmaceutical forms 
Using spectrophotometry UV-Visible to measure sample solutions of 
the pharmaceutical forms absorbance we obtained spectrum 
representative of each method, presented in fig. 3 and 4. 
 
 
Fig. 3: Spectrum of sample 1 and 2 solutions with concentration 
of 240 μg/ml, using method A at a range of 220-350 nm 
 
Analyzing fig. 3 that shows spectra of sample solution 1 (red line) 
and 2 (blue line) with a concentration of 240 μg/ml, using method A 
at a range of 220-350 nm, it can be verified that both spectrum are 
very similar presenting a peak at 276.1 nm. fig. 4 shows spectra of 
sample solution 1 (red line) and 2 (blue line) with a concentration of 
15 μg/ml, using method B at a range of 200-300 nm. The absorbance 
difference was more visible in method B than in method A, but sample 
2 also was the one presenting bigger values. 
 
 
Fig. 4: Spectrum of sample 1 and 2 solutions with concentration 
of 15 μg/ml, using method B at a range of 200-300 nm 
 
Table 7 presents the results of absorbance measurements in sample 
1 and 2 using method A and B. These absorbance measurements 
were applied in the regression equation of each method (presented 
in graphics 3 and 4) to calculate the concentrations of the samples 
(presented in table 5–1 d). 
 
Table 7: Results of absorbance measurements and quantity of FLX detected in sample 1 and 2, using Method A and B 
Parameter Method A Method B* 
Sample 1 Sample 2 Sample 1 Sample 2 
Absorbance FLX (mg) Absorbance FLX (mg) Absorbance FLX (mg) Absorbance FLX (mg) 
Mean 0.586 20.833 0.610 21.633 0.561 15.386 0.619 17.097 
SD 0.006 0.002 0.004 0.007 
RSD 1.102 0.315 0.791 1.183 
n=5, *Using this method the amount of FLX expected was 15 mg instead of 20 mg (method A). 
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Despite the expected values being different for each of 
the methods (20 mg of FLX in method A, and 15 mg of FLX in method 
B), it can be seen that in both the amount of FLX obtained is higher 
than expected. Analyzing the percentage of active ingredient, for 
method A, we obtained 104.2% and 108.2% of FLX in sample 1 and 
2, respectively; for method B we obtained 102.6% and 114% of FLX 
in sample 1 and 2, respectively. Comparing samples we verify 




The UV-Visible spectrophotometric methods that we used do not 
involve boring sample preparation, heating or extraction like other 
non-spectrophotometric methods. Besides that, they are cheap, 
sensitive, and fast and use inexpensive, readily available reagents. 
These great advantages combined with results obtained can 
contribute to their employment as a quality control tool for the 
analysis of the FLX in its formulation drug. 
The objective of the study was accomplished, since we validated two 
UV-Visible spectrophotometric methods that were in agreement 
with the requirements of ICH and Anvisa, in terms of linearity, limits 
of detection and quantification, robustness, intermediary precision 
and accuracy
In pursuit of an answer to the reports in which an initial lower 
antidepressant effect in some patients who started taking the 
generic FLX was observed, this study acknowledges that, as 
demanded by FDA and EMA, the generic form had bioequivalence 
ranging between 80 and 125% of the brand name medication. 
However, the results obtained showed that this generic form of FLX 
presented the smallest quantity of active substance when compared 
to Prozac
. However, robustness was only analyzed in method A 
due to the lack of different HCl 0.1 M supplier to analyze these 
parameters in method B. Since we have not found any previous 
articles in literature comparing generic and brand-name form in 
terms of quantity of FLX, in these study we decided to analyze a 
brand name and a generic one, so we could verify which one has the 
biggest FLX percentage.  
®
Since in this study, each of the samples was restricted to a box of a 
batch, the samples used were not representative of the global 
market. Further research can be made to compare FLX quantity in 
more generic forms with the most used brand name drug in the 
market, using bigger samples from different batches. 
 and both samples presented higher amounts of FLX than 
we expected. This may help to explain the lower antidepressant 
effect in some patients when switching from brand name to generic 
form, although meeting the recommended limits.  
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